A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status:
Terminated
Trial end date:
2018-02-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety
data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed
dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who
completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The
study consists of a screening/baseline visit followed by a 36-week OL treatment period and a
15-week follow-up period.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.